Prelude Capital Management’s Neurocrine Biosciences NBIX Stock Holding History

Prelude Capital Management’s Portfolio NBIX Stock Details NBIX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2019 Q1	–	Sell	-300	Closed	-$21K	–	2024
2018 Q4	$21K	Buy	+300	New	+$28.7K	﹤0.01%	1238
2018 Q2	–	Sell	-1,800	Closed	-$149K	–	1847
2018 Q1	$149K	Buy	+1,800	New	+$152K	0.01%	755
2015 Q1	–	Sell	-2,200	Closed	-$49K	–	2079
2014 Q4	$49K	Buy	2,200 +1,600	+267%	+$30.3K	0.01%	1246
2014 Q3	$9K	Buy	+600	New	+$8.97K	﹤0.01%	1794
2013 Q4	–	Sell	-5,100	Closed	-$58K	–	1804
2013 Q3	$58K	Buy	+5,100	New	+$70.1K	0.01%	910

Other funds holding NBIX

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Dodge & Cox San Francisco, California $182B AUM 14.68% 1-Year Est. Return

JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return

AQR Capital Management Greenwich, Connecticut $218B AUM 29.41% 1-Year Est. Return

VPM

Vanguard Portfolio Management Malvern, Pennsylvania $1.91T AUM

VCM

Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Two Sigma Investments New York $124B AUM 33.93% 1-Year Est. Return

Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

Prelude Capital Management's NBIX Position: Q1 2026 in Review

Prelude Capital Management sold out of Neurocrine Biosciences (NBIX) in Q1 2026, closing a stake of 1,808 shares — an estimated $256K sold.

Prelude Capital Management first reported a position in NBIX in Q3 2013 and held it in 26 quarters. The position peaked at $2.65M in Q3 2017. 695 funds tracked by Wall St. Rank hold NBIX as of Q1 2026.

Prelude Capital Management reported no remaining Neurocrine Biosciences position as of Q1 2026 after selling out during the quarter.
Prelude Capital Management sold 1,808 Neurocrine Biosciences shares in Q1 2026, an estimated $256K.
Prelude Capital Management first reported a position in Neurocrine Biosciences in Q3 2013 and held it in 26 quarters.
Prelude Capital Management's Neurocrine Biosciences position peaked at $2.65M in Q3 2017.
695 funds tracked by Wall St. Rank held Neurocrine Biosciences as of Q1 2026.

Based on Prelude Capital Management's 13F filing for Q1 2026, filed 15 May 2026.